CRISPR THERAPEUTICS AG Operating Income
CRISPR THERAPEUTICS AG (CRSP) reported Operating Income of -$117.27 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-03.
Financial Statements › Income Statement
us-gaap:OperatingIncomeLoss · last filed 2026-08-03
- CRISPR THERAPEUTICS AG operating income (loss) for the quarter ending 2026-06-30 was -$117.27M.
- CRISPR THERAPEUTICS AG operating income (loss) for the quarter ending 2026-03-31 was -$130.25M.
- CRISPR THERAPEUTICS AG operating income (loss) for the quarter ending 2025-12-31 was -$154.76M.
- CRISPR THERAPEUTICS AG operating income (loss) for the quarter ending 2025-09-30 was -$132.06M.
- CRISPR THERAPEUTICS AG operating income (loss) for fiscal 2025 was -$664.57M.
- CRISPR THERAPEUTICS AG operating income (loss) for fiscal 2024 was -$466.57M.
- CRISPR THERAPEUTICS AG operating income (loss) for fiscal 2023 was -$222.54M.
- CRISPR THERAPEUTICS AG operating income (loss) for fiscal 2022 was -$673.16M, a 280.22% decline from fiscal 2021.
| Period end | Operating Income (Loss) 3 month | Operating Income (Loss) 6 month | Operating Income (Loss) 9 month | Operating Income (Loss) 12 month |
|---|---|---|---|---|
| 2026-06-30 | -$117.27M 10-Q · filed 2026-08-03 | -$247.52M 10-Q · filed 2026-08-03 | -$402.28M derived: sum of 3 quarters · filed 2026-08-03 | -$534.34M derived: sum of 4 quarters · filed 2026-08-03 |
| 2026-03-31 | -$130.25M 10-Q · filed 2026-05-04 | -$285.01M derived: sum of 2 quarters · filed 2026-05-04 | -$417.07M derived: sum of 3 quarters · filed 2026-05-04 | -$646.39M derived: sum of 4 quarters · filed 2026-08-03 |
| 2025-12-31 | -$154.76M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-12 | -$286.82M derived: sum of 2 quarters · filed 2026-02-12 | -$516.15M derived: sum of 3 quarters · filed 2026-08-03 | -$664.57M 10-K · filed 2026-02-12 |
| 2025-09-30 | -$132.06M 10-Q · filed 2025-11-10 | -$361.38M derived: sum of 2 quarters · filed 2026-08-03 | -$509.81M 10-Q · filed 2025-11-10 | -$574.39M derived: sum of 4 quarters · filed 2026-08-03 |
| 2025-06-30 | -$229.32M 10-Q · filed 2026-08-03 | -$377.75M 10-Q · filed 2026-08-03 | -$442.34M derived: sum of 3 quarters · filed 2026-08-03 | -$552.47M derived: sum of 4 quarters · filed 2026-08-03 |
| 2025-03-31 | -$148.42M 10-Q · filed 2026-05-04 | -$213.01M derived: sum of 2 quarters · filed 2026-05-04 | -$323.14M derived: sum of 3 quarters · filed 2026-05-04 | -$474.40M derived: sum of 4 quarters · filed 2026-05-04 |
| 2024-12-31 | -$64.59M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-12 | -$174.72M derived: sum of 2 quarters · filed 2026-02-12 | -$325.98M derived: sum of 3 quarters · filed 2026-02-12 | -$466.57M 10-K · filed 2026-02-12 |
| 2024-09-30 | -$110.13M 10-Q · filed 2025-11-10 | -$261.39M derived: sum of 2 quarters · filed 2025-11-10 | -$401.98M 10-Q · filed 2025-11-10 | -$332.39M derived: sum of 4 quarters · filed 2026-02-12 |
| 2024-06-30 | -$151.26M 10-Q · filed 2025-08-04 | -$291.85M 10-Q · filed 2025-08-04 | -$222.26M derived: sum of 3 quarters · filed 2026-02-12 | -$354.68M derived: sum of 4 quarters · filed 2026-02-12 |
| 2024-03-31 | -$140.59M 10-Q · filed 2025-05-06 | -$71.00M derived: sum of 2 quarters · filed 2026-02-12 | -$203.41M derived: sum of 3 quarters · filed 2026-02-12 | -$298.64M derived: sum of 4 quarters · filed 2026-02-12 |
| 2023-12-31 | $69.58M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-12 | -$62.83M derived: sum of 2 quarters · filed 2026-02-12 | -$158.05M derived: sum of 3 quarters · filed 2026-02-12 | -$222.54M 10-K · filed 2026-02-12 |
| 2023-09-30 | -$132.41M 10-Q · filed 2024-11-05 | -$227.63M derived: sum of 2 quarters · filed 2024-11-05 | -$292.12M 10-Q · filed 2024-11-05 | -$423.66M derived: sum of 4 quarters · filed 2025-02-11 |
| 2023-06-30 | -$95.22M 10-Q · filed 2024-08-05 | -$159.71M 10-Q · filed 2024-08-05 | -$291.25M derived: sum of 3 quarters · filed 2025-02-11 | -$473.64M derived: sum of 4 quarters · filed 2025-02-11 |
| 2023-03-31 | -$64.49M 10-Q · filed 2024-05-08 | -$196.03M derived: sum of 2 quarters · filed 2025-02-11 | -$378.42M derived: sum of 3 quarters · filed 2025-02-11 | -$561.68M derived: sum of 4 quarters · filed 2025-02-11 |
| 2022-12-31 | -$131.54M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-11 | -$313.93M derived: sum of 2 quarters · filed 2025-02-11 | -$497.19M derived: sum of 3 quarters · filed 2025-02-11 | -$673.16M 10-K · filed 2025-02-11 |
| 2022-09-30 | -$182.39M 10-Q · filed 2023-11-06 | -$365.65M derived: sum of 2 quarters · filed 2023-11-06 | -$541.62M 10-Q · filed 2023-11-06 | -$687.32M derived: sum of 4 quarters · filed 2024-02-21 |
| 2022-06-30 | -$183.26M 10-Q · filed 2023-08-07 | -$359.23M 10-Q · filed 2023-08-07 | -$504.93M derived: sum of 3 quarters · filed 2024-02-21 | -$633.78M derived: sum of 4 quarters · filed 2024-02-21 |
| 2022-03-31 | -$175.97M 10-Q · filed 2023-05-08 | -$321.67M derived: sum of 2 quarters · filed 2024-02-21 | -$450.52M derived: sum of 3 quarters · filed 2024-02-21 | $312.10M derived: sum of 4 quarters · filed 2024-02-21 |
| 2021-12-31 | -$145.70M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-21 | -$274.55M derived: sum of 2 quarters · filed 2024-02-21 | $488.07M derived: sum of 3 quarters · filed 2024-02-21 | $373.53M 10-K · filed 2024-02-21 |
| 2021-09-30 | -$128.85M 10-Q · filed 2022-11-01 | $633.77M derived: sum of 2 quarters · filed 2022-11-01 | $519.23M 10-Q · filed 2022-11-01 | $411.46M derived: sum of 4 quarters · filed 2022-11-01 |
| 2021-06-30 | $762.62M 10-Q · filed 2022-08-08 | $648.08M 10-Q · filed 2022-08-08 | $540.31M derived: sum of 3 quarters · filed 2022-08-08 | $447.92M derived: sum of 4 quarters · filed 2022-08-08 |
| 2021-03-31 | -$114.54M 10-Q · filed 2022-05-09 | -$222.30M derived: sum of 2 quarters · filed 2022-05-09 | -$314.70M derived: sum of 3 quarters · filed 2022-05-09 | -$395.39M derived: sum of 4 quarters · filed 2022-05-09 |
| 2020-12-31 | -$107.76M 10-K · filed 2021-02-16 | -$200.16M derived: sum of 2 quarters · filed 2021-11-03 | -$280.85M derived: sum of 3 quarters · filed 2021-11-03 | -$354.44M 10-K · filed 2023-02-21 |
| 2020-09-30 | -$92.40M 10-Q · filed 2021-11-03 | -$173.09M derived: sum of 2 quarters · filed 2021-11-03 | -$246.67M 10-Q · filed 2021-11-03 | -$235.69M derived: sum of 4 quarters · filed 2021-11-03 |
| 2020-06-30 | -$80.69M 10-Q · filed 2021-07-29 | -$154.28M 10-Q · filed 2021-07-29 | -$143.29M derived: sum of 3 quarters · filed 2021-07-29 | -$4.13M derived: sum of 4 quarters · filed 2021-07-29 |
| 2020-03-31 | -$73.59M 10-Q · filed 2021-04-27 | -$62.60M derived: sum of 2 quarters · filed 2021-04-27 | $76.56M derived: sum of 3 quarters · filed 2021-04-27 | $21.58M derived: sum of 4 quarters · filed 2021-04-27 |
| 2019-12-31 | $10.98M 10-K · filed 2021-02-16 | $150.15M derived: sum of 2 quarters · filed 2021-02-16 | $95.16M derived: sum of 3 quarters · filed 2021-02-16 | $46.74M 10-K · filed 2022-02-15 |
| 2019-09-30 | $139.16M 10-K · filed 2021-02-16 | $84.18M derived: sum of 2 quarters · filed 2021-02-16 | $35.76M 10-Q · filed 2020-10-28 | -$9.47M derived: sum of 4 quarters · filed 2021-02-16 |
| 2019-06-30 | -$54.98M 10-K · filed 2021-02-16 | -$103.41M 10-Q · filed 2020-07-27 | -$148.63M derived: sum of 3 quarters · filed 2021-02-16 | -$198.07M derived: sum of 4 quarters · filed 2021-02-16 |
| 2019-03-31 | -$48.42M 10-K · filed 2021-02-16 | -$93.65M derived: sum of 2 quarters · filed 2021-02-16 | -$143.08M derived: sum of 3 quarters · filed 2021-02-16 | -$180.37M derived: sum of 4 quarters · filed 2021-02-16 |
| 2018-12-31 | -$45.23M 10-K · filed 2020-02-12 | -$94.66M derived: sum of 2 quarters · filed 2020-02-12 | -$131.95M derived: sum of 3 quarters · filed 2020-02-12 | -$158.94M 10-K · filed 2021-02-16 |
| 2018-09-30 | -$49.43M 10-K · filed 2020-02-12 | -$86.72M derived: sum of 2 quarters · filed 2020-02-12 | -$113.72M 10-Q · filed 2019-10-28 | -$112.74M derived: sum of 4 quarters · filed 2020-02-12 |
| 2018-06-30 | -$37.29M 10-K · filed 2020-02-12 | -$64.28M 10-Q · filed 2019-07-29 | -$63.31M derived: sum of 3 quarters · filed 2020-02-12 | -$86.88M derived: sum of 4 quarters · filed 2020-02-12 |
| 2018-03-31 | -$27.00M 10-K · filed 2020-02-12 | -$26.02M derived: sum of 2 quarters · filed 2020-02-12 | -$49.59M derived: sum of 3 quarters · filed 2020-02-12 | -$70.90M derived: sum of 4 quarters · filed 2020-02-12 |
| 2017-12-31 | $972.00K 10-K · filed 2019-02-25 | -$22.60M derived: sum of 2 quarters · filed 2019-02-25 | -$43.90M derived: sum of 3 quarters · filed 2019-02-25 | -$64.65M 10-K · filed 2020-02-12 |
| 2017-09-30 | -$23.57M 10-K · filed 2019-02-25 | -$44.88M derived: sum of 2 quarters · filed 2019-02-25 | -$65.62M 10-Q · filed 2018-11-07 | -$90.93M derived: sum of 4 quarters · filed 2019-02-25 |
| 2017-06-30 | -$21.31M 10-K · filed 2019-02-25 | -$42.05M 10-Q · filed 2018-08-07 | -$67.36M derived: sum of 3 quarters · filed 2019-02-25 | -$81.97M derived: sum of 4 quarters · filed 2019-02-25 |
| 2017-03-31 | -$20.74M 10-K · filed 2019-02-25 | -$46.05M derived: sum of 2 quarters · filed 2019-02-25 | -$60.66M derived: sum of 3 quarters · filed 2019-02-25 | -$77.22M derived: sum of 4 quarters · filed 2019-02-25 |
| 2016-12-31 | -$25.31M 10-K · filed 2018-03-08 | -$39.92M derived: sum of 2 quarters · filed 2018-03-08 | -$56.48M derived: sum of 3 quarters · filed 2018-03-08 | -$68.13M 10-K · filed 2019-02-25 |
| 2016-09-30 | -$14.61M 10-K · filed 2018-03-08 | -$31.17M derived: sum of 2 quarters · filed 2018-03-08 | -$42.82M 10-Q · filed 2017-11-08 | -$54.99M derived: sum of 4 quarters · filed 2018-03-08 |
| 2016-06-30 | -$16.56M 10-K · filed 2018-03-08 | -$28.21M 10-Q · filed 2017-08-10 | -$40.38M derived: sum of 3 quarters · filed 2018-03-08 | -$46.58M derived: sum of 4 quarters · filed 2018-03-08 |
| 2016-03-31 | -$11.65M 10-K · filed 2018-03-08 | -$23.82M derived: sum of 2 quarters · filed 2018-03-08 | -$30.02M derived: sum of 3 quarters · filed 2018-03-08 | -$33.65M derived: sum of 4 quarters · filed 2018-03-08 |
| 2015-12-31 | -$12.17M 10-K · filed 2017-03-10 | -$18.37M derived: sum of 2 quarters · filed 2017-03-10 | -$21.99M derived: sum of 3 quarters · filed 2017-03-10 | -$25.73M 10-K · filed 2018-03-08 |
| 2015-09-30 | -$6.20M 10-K · filed 2017-03-10 | -$9.83M derived: sum of 2 quarters · filed 2017-03-10 | -$13.56M 10-Q · filed 2016-11-22 | |
| 2015-06-30 | -$3.63M 10-K · filed 2017-03-10 | -$7.36M derived: sum of 2 quarters · filed 2017-03-10 | ||
| 2015-03-31 | -$3.74M 10-K · filed 2017-03-10 | |||
| 2014-12-31 | -$6.63M 10-K · filed 2017-03-10 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| IOVANCE BIOTHERAPEUTICS, INC. (IOVA) | United States | $4.897B | -6.51 |
| Scholar Rock Holding Corp (SRRK) | United States | $5.920B | -16.37 |
| Adaptive Biotechnologies Corp (ADPT) | United States | $4.719B | -53.43 |
| CG Oncology, Inc. (CGON) | United States | $6.095B | -27.95 |
| Relay Therapeutics, Inc. (RLAY) | United States | $3.884B | -14.30 |
| Immunovant, Inc. (IMVT) | United States | $7.028B | -14.78 |
| Tarsus Pharmaceuticals, Inc. (TARS) | United States | $3.329B | -58.60 |
| Denali Therapeutics Inc. (DNLI) | United States | $3.274B | -8.04 |
| Beam Therapeutics Inc. (BEAM) | United States | $2.549B | -41.51 |
| Greenland Mines Ltd (GRML) | United States | $2.362B |